Advertisement

AAPS PharmSciTech

, 20:156 | Cite as

Systematically Optimized Imiquimod-Loaded Novel Hybrid Vesicles by Employing Design of Experiment (DoE) Approach with Improved Biocompatibility, Stability, and Dermatokinetic Profile

  • Mandeep Sharma
  • Gajanand Sharma
  • Bhupinder Singh
  • Om Prakash KatareEmail author
Research Article
  • 77 Downloads

Abstract

The present research work explored the possibility of harnessing the benefits of vesicular carriers for overcoming imiquimod-associated complaints or side effects. Hybrid vesicles were prepared by the most common and easily scalable method, i.e., thin film hydration. The chaffing of myriad of factors, both process and material related, affecting the desirable attributes of conceived vesicles, was performed through Taguchi design. Based upon the analysis of Pareto chart and prior experiences, concentration of phospholipid and poloxamer 407 was selected for optimization by 2 levels, 13 run central composite design (CCD). The optimized hybrid vesicles contained 1% w/v phospholipid and 3% w/v poloxamer 407. The optimized hybrid vesicles were incorporated into the 3% w/v carbopol 940 gel and characterized for morphology, physicochemical properties, and rheological behavior. The release (%) and skin retention (% of total dose) across rat skin from gel at same amount of formulation was more than Imiquad®. The gel delivered the loaded cargo, preferably, in the viable region of skin and formed local depot in confocal microscopic studies. The gel followed one compartment open body dermatokinetic model in rat skin. There was not any harmful effect on the mice skin after repeated applications. The gel was stable at room conditions for 1 year.

KEY WORDS

Design of experiment Vesicles Imiquimod Gel Dermatokinetics 

Abbreviations

CCD

Central composite design

Jss

Study state permeation flux

USA

United State of America

FESEM

Field emission scanning electron microscope

Notes

Acknowledgments

The authors acknowledge Stat-Ease, Inc. Minneapolis, USA, for providing requisite software (Design Expert v10.0) to Mr. Gajanand Sharma, Panjab University, Chandigarh to perform optimization studies with his expert advice. The various department of the Panjab University Chandigarh viz., Department of Geology, Centre for Potential in Excellence in Basic Medical Sciences and UGC Center of Excellence in Applications of Nanomaterials, Nanoparticles and Nanocomposites, and SAIF, CIL, and UCIM as well as sections of UIPS have helped in completing the research work and authors acknowledge the contribution of their authorities, staff, and students.

Funding

This work was supported by the University Grant Commission, New Delhi (F.4-1/2006 (BSR)/5-94/2007 (BSR) dated 03.05.2013 and 7858/UIPS date 14/3/14).

Compliance with Ethical Standards

All animal studies were approved by Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) of Panjab University (Approval number- PU/45/99/CPCSEA/IAEC/2018/117).

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Cantisani C, Lazic T, Richetta AG, Clerico R, Mattozzi C, Calvieri S. Imiquimod 5% cream use in dermatology, side effects and recent patents. Recent Patents Inflamm Allergy Drug Discov. 2012;6(1):65–9.CrossRefGoogle Scholar
  2. 2.
    Wagstaff AJ, Perry CM. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs. 2007;67(15):2187–210.CrossRefGoogle Scholar
  3. 3.
    Walter A, Schäfer M, Cecconi V, Matter C, Urosevic-Maiwald M, Belloni B, et al. Aldara activates TLR7-independent immune defence. Nat Commun. 2013;4:1560.CrossRefGoogle Scholar
  4. 4.
    Tandon Y, Brodell RT. Local reactions to imiquimod in the treatment of basal cell carcinoma. Dermatol Online J. 2012;18(9):1.PubMedGoogle Scholar
  5. 5.
    Winckle G, Osborne DW. Imiquimod formulation. In: USPTO, editor. USPTO. U.S.A.: Dow Pharmaceutials Science, U.S.A.; 2008.Google Scholar
  6. 6.
    Alavi M, Karimi N, Safaei M. Application of various types of liposomes in drug delivery systems. Adv Pharm Bull. 2017;7(1):3–9.CrossRefGoogle Scholar
  7. 7.
    Biju SS, Talegaonkar S, Mishra PR, Khar RK. Vesicular systems: an overview. Indian J Pharm Sci. 2006;68(2):141–53.CrossRefGoogle Scholar
  8. 8.
    Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12.CrossRefGoogle Scholar
  9. 9.
    Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol. 2016;44(1):381–91.CrossRefGoogle Scholar
  10. 10.
    Fox CB, Sivananthan SJ, Duthie MS, Vergara J, Guderian JA, Moon E, et al. A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7. J Nanobiotechnol. 2014;12(17):10.Google Scholar
  11. 11.
    Ma M, Wang J, Guo F, Lei M, Tan F, Li N. Development of nanovesicular systems for dermal imiquimod delivery: physicochemical characterization and in vitro/in vivo evaluation. J Mater Sci Mater Med. 2015;26(6):191.CrossRefGoogle Scholar
  12. 12.
    Jun S, Huidi Z, Yanting W. Liposome gel preparation capable of inhibiting scar hypertrophy and preparation and application thereof. In: EPO, editor. EPO. China: Univ Guangdong Pharm, Guangzhou, China; 2017.Google Scholar
  13. 13.
    Cavazzuti M. Design of experiments. In: Cavazzuti M, editor. From theory to design scientific and technological aspects in mechanics. Verlag Berlin Heidelberg: Springer; 2013. p. 13–42.Google Scholar
  14. 14.
    Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic “design of experiments.” Part I: fundamental aspects. Crit Rev Ther Drug Carrier Syst. 2004;22(1):27–105.CrossRefGoogle Scholar
  15. 15.
    Garg V, Singh H, Bhatia A, Raza K, Singh SK, Singh B, et al. Systematic development of transethosomal gel system of piroxicam: formulation optimization, in vitro evaluation, and ex vivo assessment. AAPS PharmSciTech. 2017;18(1):58–71.CrossRefGoogle Scholar
  16. 16.
    Kassem MA, Megahed MA, Elyazid SKA, Abd-Allah FI, Abdelghany TM, Al-Abd AM, et al. Enhancing the therapeutic efficacy of tamoxifen citrate loaded span-based nano-vesicles on human breast adenocarcinoma cells. AAPS PharmSciTech. 2018;19(4):1529–43.CrossRefGoogle Scholar
  17. 17.
    Morsi NM, Aboelwafa AA, Dawoud MHS. Enhancement of the bioavailability of an antihypertensive drug by transdermal protransfersomal system: formulation and in vivo study. J Liposome Res. 2018;28(2):137–48.CrossRefGoogle Scholar
  18. 18.
    Donnelly RF, McCarron PA, Zawislak AA, Woolfson AD. Design and physicochemical characterisation of a bioadhesive patch for dose-controlled topical delivery of imiquimod. Int J Pharm. 2006;307(2):318–25.CrossRefGoogle Scholar
  19. 19.
    Zhao B, Rong YZ, Huang XH, Shen JS. Experimental and theoretical study on the structure and electronic spectra of imiquimod and its synthetic intermediates. Bioorg Med Chem Lett. 2007;17(17):4942–6.CrossRefGoogle Scholar
  20. 20.
    Harmonisation IC. Validation of analytical procedures: text and methodology Q2(R1). Geneva, Switzerland: International Conference on Hormonisation; 1996. p. 1–17.Google Scholar
  21. 21.
    Jagdale S, Pawar S. Gellified emulsion of ofloxacin for transdermal drug delivery system. Adv Pharm Bull. 2017;7(2):229–39.CrossRefGoogle Scholar
  22. 22.
    Raza K, Singh B, Singla S, Wadhwa S, Garg B, Chhibber S, et al. Nanocolloidal carriers of isotretinoin: antimicrobial activity against Propionibacterium acnes and dermatokinetic modeling. Mol Pharm. 2013;10(5):1958–63.CrossRefGoogle Scholar
  23. 23.
    Bhatia A, Raza K, Singh B, Katare OP. Phospholipid-based formulation with improved attributes of coal tar. J Cosmet Dermatol. 2009;8(4):282–8.CrossRefGoogle Scholar
  24. 24.
    Jain A, Jain SK. In vitro release kinetics model fitting of liposomes: an insight. Chem Phys Lipids. 2016;201(1):28–40.CrossRefGoogle Scholar
  25. 25.
    Shargel L, Wu-Pong S, Yu ABC. Applied biopharmaceutics & pharmacokinetics. 5th ed. United State of America: MaGraw-Hill Companies, Inc.; 2004.Google Scholar
  26. 26.
    Thotakura N, Kumar P, Wadhwa S, Raza K, Katare P. Dermatokinetics as an important tool to assess the bioavailability of drugs by topical nanocarriers. Curr Drug Metab. 2017;18(5):404–11.CrossRefGoogle Scholar
  27. 27.
    Hormonization IC. Stability testing of new drug substances and drug products. Q1A(R2). Geneva, Switzerland: International Conference on Hormonization; 2003. p. 24.Google Scholar
  28. 28.
    Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic “design of experiments.” Part I: fundamental aspects. Crit Rev Ther Drug Carrier Syst. 2005;22(1):27–105.CrossRefGoogle Scholar
  29. 29.
    Duman G, Aslan İ, Özer AY, İnanç İ, Taralp A. Liposome, gel and lipogelosome formulations containing sodium hyaluronate. J Liposome Res. 2014;24(4):259–69.CrossRefGoogle Scholar
  30. 30.
    Tan HW, Misran M. Characterization of fatty acid liposome coated with low-molecular-weight chitosan. J Liposome Res. 2012;22(4):329–35.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  • Mandeep Sharma
    • 1
  • Gajanand Sharma
    • 1
  • Bhupinder Singh
    • 1
    • 2
  • Om Prakash Katare
    • 1
    Email author
  1. 1.University Institute of Pharmaceutical Sciences, UGC Centre of Advanced StudiesPanjab UniversityChandigarhIndia
  2. 2.UGC-Centre of Excellence in Applications of Nanomaterials, Nanoparticles and NanocompositesPanjab UniversityChandigarhIndia

Personalised recommendations